scispace - formally typeset
R

Roland E. Schmieder

Researcher at University of Erlangen-Nuremberg

Publications -  780
Citations -  85811

Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.

Papers
More filters
Journal ArticleDOI

Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study

TL;DR: The data indicate an additive antiproteinuric effect of ultrahigh dose of the angiotensin receptor blocker candesartan compared with standard dose.
Journal ArticleDOI

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

TL;DR: SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in tissue sodium content of the skin after 6 weeks, which point to a decrease of total sodium content in patients with type 2 diabetes prone to cardiovascular complications, that might be mitigated by SGLT -2 inhibition.
Journal ArticleDOI

Impact of New-Onset Diabetes Mellitus on Development of Atrial Fibrillation and Heart Failure in High-Risk Hypertension (from the VALUE Trial)

TL;DR: In this paper, the influence of new-onset DM on developing atrial fibrillation (AF) was investigated in the VALUE trial population of high-risk hypertensive patients.
Journal ArticleDOI

Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients

TL;DR: Endothelial function of the retinal vasculature is impaired in early essential hypertension but can be improved by AT1-receptor blockade.
Journal ArticleDOI

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.

TL;DR: Short-term lipid-lowering therapy with statins is able to improve endothelium-dependent vasodilation and NO availability almost completely after 3 days in hypercholesterolemic patients probably by decreasing oxidative stress.